Continuous Glucose Monitoring Market Trends & Summary

The global Continuous Glucose Monitoring (CGM) Market is witnessing robust expansion, reflecting the world’s accelerating shift toward real-time digital health technologies for chronic disease management. According to Renub Research, the market, valued at US$ 6.82 billion in 2024, is expected to grow steadily at a CAGR of 8.41%, reaching US$ 14.1 billion by 2033. This rise comes at a pivotal time, with global diabetes cases climbing at an alarming pace and healthcare systems embracing more connected, preventive, and patient-centric digital solutions.

As governments, tech innovators, and medical device makers work toward easing the burden of diabetes—a disease that affects well over half a billion people globally—the role of CGM devices has shifted from optional to essential. These devices provide continuous, real-time glucose readings with minimal invasiveness, allowing individuals and clinicians to track glucose fluctuations with unprecedented accuracy and convenience.

This report explores the dynamics of the global CGM market, emerging trends, segmentation analysis, and regional performance, while unpacking the growth factors, hurdles, and future outlook of one of the world’s fastest-growing digital healthcare markets.

Understanding the Continuous Glucose Monitoring Market

Continuous Glucose Monitoring (CGM) systems have revolutionized diabetes management. Unlike traditional finger-stick tests, which provide just a snapshot of current glucose levels, CGM devices monitor glucose continuously—day and night—using a tiny sensor inserted under the skin. The sensor measures glucose in the interstitial fluid and transmits readings to a receiver, smartphone, or cloud platform.

CGM systems track trends, warn users when glucose levels are rising or falling, and offer vital data on how diet, exercise, stress, medication, and sleep patterns affect glucose. For individuals with Type 1 diabetes and insulin-dependent Type 2 diabetes, this real-time insight dramatically improves glycemic control, reduces hypoglycemic events, and supports informed clinical decisions.

In clinical settings, CGM systems are increasingly used to monitor critically ill patients, surgical cases, and those requiring tight glycemic management. As healthcare becomes more digitized, CGM technology is emerging as a key pillar of next-generation diabetes management.

Market Growth Drivers

1. Rising Global Diabetes Burden

The foremost driver of CGM market expansion is the staggering global rise in diabetes. Today, 537 million adults aged 20–79 are living with diabetes, roughly 1 in 10 people worldwide. This figure is projected to soar to:

643 million by 2030

783 million by 2045

The prevalence of diabetes has doubled since 1990, rising from 7% to 14% among adults. Even more concerning is the absence of consistent management—59% of adults aged 30+ did not take diabetes medications in 2022.

As diabetes continues to surge, CGM adoption becomes indispensable. Real-time monitoring offers significant benefits for disease management, early intervention, and reducing hospitalizations—especially in aging populations and obesity-driven diabetes hotspots.

2. Technological Advancements in CGM Devices

Innovation is accelerating across the CGM ecosystem. Industry leaders are pushing boundaries with:

Longer sensor life (14–90 days)

Higher accuracy MARD scores

Calibration-free sensors

Seamless smartphone integration

AI-powered predictive alerts

Closed-loop insulin delivery systems

One notable development occurred in August 2024, when Abbott partnered with Medtronic to build an integrated CGM-insulin system powered by Abbott’s FreeStyle Libre technology. Such collaborations support the shift toward fully automated diabetes care.

Wearable CGMs continue to shrink in size while becoming more comfortable, less invasive, and more user-friendly. This tech-forward evolution is dramatically boosting adoption rates globally.

3. Growing Popularity of Homecare and Remote Monitoring

A major factor driving CGM adoption is the global shift toward home-based healthcare. CGM enables patients to track glucose levels without frequent clinic visits, significantly improving quality of life and reducing healthcare costs.

Through advanced connectivity features, users can share data with healthcare professionals from home, supporting personalized diabetes management. CGM is especially beneficial for:

Geriatric patients

Pediatric patients

Individuals with mobility challenges

Patients transitioning from hospital to home care

As telemedicine and virtual care gain prominence, CGM becomes an essential component of remote patient monitoring systems.

Market Challenges

1. High Device and Maintenance Costs

Cost remains the biggest obstacle, especially in price-sensitive markets. CGM devices require not only the initial sensor and receiver but recurring sensor replacements every 10–14 days. This makes long-term maintenance expensive, particularly without robust insurance coverage.

In many low- and middle-income countries, out-of-pocket costs limit accessibility despite rising awareness and demand.

2. Accuracy and Technical Limitations

Although advancements have significantly improved CGM accuracy, occasional discrepancies between blood glucose and interstitial fluid readings persist. Some users experience:

Calibration issues

Sensor adhesion problems

False alerts

Discomfort during insertion

These limitations hinder user confidence and slow adoption in certain regions. Continued R&D is essential to overcome these barriers.

Market Segments Analysis

By Component

1. Sensors

Sensors form the backbone of CGM systems. They continuously measure glucose levels and communicate data to transmitters or receivers. Innovations center around:

Longer lifespan

Reduced calibration

Higher comfort

Smaller size

Given their frequent replacement cycle, sensors represent the largest revenue-generating component of the CGM market.

2. Transmitters

Transmitters connect sensors to external devices (smartphones, receivers). Increasing compatibility with digital health platforms boosts this segment’s demand.

3. Receivers

Receivers display glucose readings and trends. While smartphones are replacing them in some markets, receivers remain important for pediatric, elderly, and clinical users who prefer dedicated monitoring devices.

By End User

1. Hospitals

Hospitals are rapidly adopting CGM systems for critically ill and diabetic inpatients. They help clinicians monitor real-time fluctuations, especially during surgery, ICU management, and emergency care.

2. Homecare Settings

Homecare is the fastest-growing CGM end-user segment. The combination of remote monitoring, reduced hospital visits, and personalized care drives its popularity.

3. Others

Clinics, emergency care units, and long-term care facilities also contribute significantly to market demand.

Regional Market Analysis

United States

The U.S. leads the global CGM market due to:

High diabetes prevalence

Advanced healthcare infrastructure

Extensive insurance coverage

Strong patient awareness

Large investments in digital health

The CDC reports 98 million adults (37%) have prediabetes, with most unaware of their condition. This silent progression strengthens the case for widespread CGM adoption.

Germany

Germany represents a major European CGM hub. Factors fueling growth include:

Expanding diabetic population

Robust healthcare coverage

Government-led digitization initiatives

In January 2023, LifeScan published significant real-world evidence from over 144,000 patients demonstrating improved control using Bluetooth-connected glucose meters and mobile apps—validated data that strengthens CGM adoption.

India

India is a dynamic, fast-growing CGM market driven by:

One of the world’s largest diabetic populations

Growing awareness

Rising telemedicine adoption

Expansion of cost-effective CGM solutions

A February 2023 collaboration between Dario Health and Dexcom integrated Dexcom’s CGM into Dario’s chronic care platform, boosting accessibility.

Brazil

Brazil’s CGM market benefits from increased healthcare investment and government support. Despite high device costs, global manufacturers are entering the region.

In October 2023, GlucoModicum and Molex partnered to develop a needle-free, non-invasive CGM, marking a promising shift in future device design.

UAE

The UAE is emerging as a high-growth CGM region, supported by:

Strong government backing

Digital healthcare transformation

High disposable income

Rising lifestyle diseases

In October 2023, PureHealth reported over 140,000 downloads of its AI-powered app “Pura,” reflecting the region’s rapid adoption of personalized digital health tools.

Key Players Covered

Renub Research profiles major companies including:

Abbott Laboratories

Roche

Tandem Diabetes Care

DexCom Inc.

Senseonics Holdings Inc.

Ypsomed Holding AG

Medtronic Plc

i-Sens Inc.

Each is evaluated from four viewpoints—Overview, Key Person, Recent Developments, and Revenue.

Final Thoughts

The global Continuous Glucose Monitoring market is on a transformative path. With diabetes cases rising rapidly, CGM systems are no longer seen as optional health accessories—they have become life-saving medical tools at the core of modern diabetes care. Backed by technological innovation, remote monitoring trends, personalized health insights, and strong regional adoption, the market is positioned for sustained long-term growth.

As the world embraces digital health solutions, CGM devices stand at the forefront, bridging the gap between preventive care, personalized medicine, and smart healthcare ecosystems. The next decade will likely witness even more integration with AI, insulin pumps, mobile health platforms, and potentially non-invasive CGM technologies—making diabetes management simpler, safer, and smarter for millions across the globe.